|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ernani V and Stinchcombe TE: Management of
brain metastases in non-small-cell lung cancer. J Oncol Pract.
15:563–570. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Planchard D, Popat S, Kerr K, Novello S,
Smit E, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29:iv192–iv237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Jong D, Das JP, Ma H, Valiplackal JP,
Prendergast C, Roa T, Braumuller B, Deng A, Dercle L, Yeh R, et al:
Novel targets, novel treatments: The changing landscape of
non-small cell lung cancer. Cancers (Basel). 15:28552023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok TS, Wu YL, Kudaba I, Kowalski DM, Cho
BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or
metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised,
open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reck M, Rodríguez-Abreu D, Robinson A, Hui
R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et
al: 2016. Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gandhi L, Rodrguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Eng J Med. 373:1627–1639. 2015. View Article : Google Scholar
|
|
10
|
Demaria S and Formenti SC: Radiation as an
immunological adjuvant: Current evidence on dose and fractionation.
Front Oncol. 2:1532012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G,
McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M,
Stewart R, et al: Acquired resistance to fractionated radiotherapy
can be overcome by concurrent PD-L1 blockade. Cancer Res.
74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Victor CTS, Rech AJ, Maity A, Rengan R,
Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al:
Radiation and dual checkpoint blockade activate non-redundant
immune mechanisms in cancer. Nature. 520:373–377. 2015. View Article : Google Scholar
|
|
14
|
Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou
F and Zhou C: Combined radiotherapy and anti-PD-L1 antibody
synergistically enhances antitumor effect in non-small cell lung
cancer. J Thor Oncol. 12:1085–1097. 2017. View Article : Google Scholar
|
|
15
|
Zeng J, See AP, Phallen J, Jackson CM,
Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E,
et al: Anti-PD-1 blockade and stereotactic radiation produce
long-term survival in mice with intracranial gliomas. Int J Radiat
Oncol Biol Phys. 86:343–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dovedi SJ, Cheadle EJ, Popple AL, Poon E,
Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO,
et al: Fractionated radiation therapy stimulates antitumor immunity
mediated by both resident and infiltrating polyclonal T-cell
populations when combined with PD-1 blockade. Clin Cancer Res.
23:5514–5526. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group, : Preferred Reporting items for systematic
reviews and meta analyses: The PRISMA statement. PloS Med.
6:e123–e130. 2009. View Article : Google Scholar
|
|
18
|
Grimaldi S, Terroir M and Caramella C:
Advances in oncological treatment: Limitations of RECIST 1.1
criteria. Q J Nucl Med Mol Imaging. 62:129–139. 2017.PubMed/NCBI
|
|
19
|
Shepard MJ, Xu Z, Donahue J, Muttikkal
TJE, Cordeiro D, Hansen L, Mohammed N, Gentzler RD, Larner J, Fadul
CE and Sheehan JP: Stereotactic radiosurgery with and without
checkpoint inhibition for patients with metastatic non-small cell
lung cancer to the brain: A matched cohort study. J Neurosurg.
133:685–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen L, Douglass J, Kleinberg L, Ye X,
Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers
H, et al: Concurrent immune checkpoint inhibitors and stereotactic
radiosurgery for brain metastases in non-small cell lung cancer,
melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys.
100:916–925. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Z, Feng J, Weng Y, Jin Y and Peng M:
Combination of immune checkpoint inhibitors and radiotherapy for
advanced non-small-cell lung cancer and prostate cancer: A
meta-analysis. J Oncol. 2021:66316432021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian S, Switchenko JM, Buchwald ZS, Patel
PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera
M, et al: Lung stereotactic body radiation therapy and concurrent
immunotherapy: A multicenter safety and toxicity analysis. Int J
Radiat Oncol Biol Phys. 108:304–313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Theelen WS, Peulen HM, Lalezari F, van der
Noort V, de Vries JF, Aerts JG, Dumoulin DW, Bahce I, Niemeijer AN,
de Langen AJ, et al: Effect of pembrolizumab after stereotactic
body radiotherapy vs pembrolizumab alone on tumor response in
patients with advanced non-small cell lung cancer: Results of the
PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol.
5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang P, Yin T, Zhao K, Yu J and Teng F:
Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1
inhibitors for oligometastatic non-small cell lung cancer. J Cancer
Res Clin Oncol. 148:1253–1261. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pakkala S, Higgins K, Chen Z, Sica G,
Steuer C, Zhang C, Zhang G, Wang S, Hossain MS, Nazha B, et al:
Durvalumab and tremelimumab with or without stereotactic body
radiation therapy in relapsed small cell lung cancer: A randomized
phase II study. J Immunother Cancer. 8:e0013022020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schoenfeld JD, Giobbie-Hurder A,
Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler
RD, Lee C, et al: Durvalumab, tremelimumab alone or in combination
with low-dose or hypofractionated targeted radiotherapy in
metastatic non-small cell lung cancer refractory to Prior PD-1
therapy: A multicentre, open-label, randomized, phase 2 trial.
Lancet Oncol. 23:279–291. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seidel JA, Otsuka A and Kabashima K:
Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of
action, efficacy, and limitations. Front Oncol. 8:862018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Young KH, Baird JR, Savage T, Cottam B,
Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS,
et al: Optimizing timing of immunotherapy improves control of
tumors by hypofractionated radiation therapy. PLoS One.
11:e01571642016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
ElJalby M, Pannullo SC, Schwartz TH,
Parashar B and Wernicke AG: Optimal timing and sequence of
immunotherapy when combined with stereotactic radiosurgery in the
treatment of brain metastases. World Neurosurg. 127:397–404. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bockel S, Antoni D, Deutsch É and Mornex
F: Immunotherapy and radiotherapy. Cancer Radiother. 21:244–255.
2017.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chicas-Sett R, Morales-Orue I,
Castilla-Martinez J, Zafra-Martin J, Kannemann A, Blanco J, Lloret
M and Lara PC: Stereotactic ablative radiotherapy combined with
immune checkpoint inhibitors reboots the immune response assisted
by immunotherapy in metastatic lung cancer: A systematic review.
Int J Mol Sci. 20:21732019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trapani S, Manicone M, Sikokis A,
D'Abbiero N, Salaroli F, Ceccon G and Buti S: Effectiveness and
safety of ‘real’ concurrent stereotactic radiotherapy and
immunotherapy in metastatic solid tumors: A systematic review. Crit
Rev Oncol Hematol. 142:9–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perrinjaquet C, Zaher M, Ferraro DA, Comte
D, Trueb L, Zimmermann S, Coukos G and Orcurto A: Side effects of
immune checkpoint inhibitors: Diagnosis and management. Revue Med
Suisse. 15:1010–1016. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vanpouille-Box C, Diamond JM, Pilones KA,
Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH and Demaria S:
TGFβ is a master regulator of radiation therapy-induced antitumor
immunity. Cancer Res. 75:2232–2242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gray JE, Villegas A, Daniel D, Vicente D,
Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, et al:
Three-year overall survival with durvalumab after chemoradiotherapy
in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 15:288–293.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ross HJ, Kozono DE, Urbanic JJ, Williams
TM, DuFrane C, Bara I, Schulze K, Brockman JM, Wang XF, Gao J, et
al: AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab
and chemoradiation (CRT) for stage III non-small cell lung cancer
(NSCLC). Wolters Kluwer Health. 2021.
|
|
37
|
Greenwald RJ, Freeman GJ and Sharpe AH:
The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zou W and Chen L: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kucuk A, Topkan E, Durankus NK, Senyurek
S, Akdemir EY, Sezen D, Bolukbasi Y, Selek U, Pehlivan B and Sergi
CM: Combined stereotactic radiosurgery and immune checkpoint
inhibitors for the treatment of brain metastasis. Exon
Publications. 57–74. 2023.
|
|
40
|
Deng L, Liang H, Burnette B, Weicheslbaum
RR and Fu YX: Radiation and anti-PD-L1 antibody combinatorial
therapy induces T cell-mediated depletion of myeloid-derived
suppressor cells and tumor regression. Oncoimmunology.
3:e284992014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Knispel S, Stang A, Zimmer L, Lax H,
Gutzmer R, Heinzerling L, Weishaupt C, Pföhler C, Gesierich A,
Herbst R, et al: Impact of a preceding radiotherapy on the outcome
of immune checkpoint inhibition in metastatic melanoma: A
multicenter retrospective cohort study of the DeCOG. J Immunother
Cancer. 8:e0003952020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma X, Zhang Y, Wang S, Wei H and Yu J:
Immune checkpoint inhibitor (ICI) combination therapy compared to
monotherapy in advanced solid cancer: A systematic review. J
Cancer. 12:1318–1333. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shevtsov M, Sato H, Multhoff G and Shibata
A: Novel approaches to improve the efficacy of immuno-radiotherapy.
Front Oncol. 9:1562019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Singh C, Qian JM, James BY and Chiang VL:
Local tumor response and survival outcomes after combined
stereotactic radiosurgery and immunotherapy in non-small cell lung
cancer with brain metastases. J Neurosurg. 132:512–517. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hwang WL, Niemierko A, Hwang KL, Hubbeling
H, Schapira E, Gainor JF and Keane FK: Clinical outcomes in
patients with metastatic lung cancer treated with PD-1/PD-L1
inhibitors and thoracic radiotherapy. JAMA Oncol. 4:253–255. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Naidoo J, Wang X, Woo KM, Iyriboz T,
Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin
AM, et al: Pneumonitis in patients treated with anti-programmed
death-1/programmed death ligand 1 therapy. J Clin Oncol.
35:709–717. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim DY, Kim PH, Suh CH, Kim KW and Kim HS:
Immune checkpoint inhibitors with or without radiotherapy in
non-small cell lung cancer patients with brain metastases: A
systematic review and meta-analysis. Diagnostics (Basel).
10:10982020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu Z, Xu T, Chang P, Fu W, Wei J, Xia C,
Wang Q, Li M, Pu X, Huang F, et al: Efficacy and safety of immune
checkpoint inhibitors with or without radiotherapy in metastatic
non-small cell lung cancer: A systematic review and meta-analysis.
Front Pharmacol. 14:10642272023. View Article : Google Scholar : PubMed/NCBI
|
